Has anyone else been seeing this?
Hi Jim,
We are seeing increase in new cases of non-invasive/in-situ neoplasm of pancreas and lung and occasional breast where the diagnosis is made on imaging or by direct visualization and not confirmed histologically as non-invasive/in–situ cancer. They may or may not treat the patient – some end up being watch and wait such as the broncho-alveolar carcinoma of lung histologies.
This combination of in-situ/non-invasive without histologic confirmation of behavior is not valid for SEER IF31 – the Diagnostic Confirmation, Behavior Edit.
We can set the Histology Override Field – but, then we actually lose the ability to find them later. So, we might want to focus this with more attention to these exceptions in near-term edit updates.
For pancreas these are diagnosed on EUS or direct visualization and include histology such as IPMN (8453/2 – intraductal papillary mucinous neoplasm) and ITPN (8503/2 – intraductal tubule-papillary neoplasm) and MCN (8470/2 – mucinous cystadenocarcinoma, non-invasive). We mostly see IPMN dx from EUS in Florida.
For lung these are diagnosed on CT imaging and include what were previously termed “broncho-alveolar carcinoma” or BAC and subtypes such as lepidic and acinar adenocarcinoma of lung, etc.
For breast – most MRI studies that are trying to establish DCIS dx or LCIS dx are still in trial – but, headed in same direction.
Thx, Steve
Steven Peace, CTR
FCDS Senior Manager Research Support
Florida Cancer Data System
University of Miami Miller School of Medicine
P.O. Box 016960 (D4-11)
Miami, FL 33101
Phone: (305)-243-4601
Fax: (305)-243-4871
FCDS Web Site: http://fcds.med.miami.edu